Loading
A new target, FGFR2b, showed a survival gain at first look that shrank with longer follow-up, and the trial did not include the immunotherapy patients now routinely get.
Interim analysis: OS 17.9 vs 12.5 months (HR 0.61, p=0.005). Updated analysis (ESMO 2025) showed the difference attenuate and lose significance. The chemotherapy-only control (no PD-1) and ocular toxicity (corneal events in most patients) limit interpretation. FORTITUDE-102 tests the combination with nivolumab.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
547 enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survival (interim)primary | Bemarituzumab + mFOLFOX6 | - | 17.9 months | 0.61 | 0.005 | link |
| Placebo + mFOLFOX6 | - | 12.5 months |
Shares Amgen, Monoclonal antibodies.
Shares Amgen, Monoclonal antibodies.
Shares Amgen, Monoclonal antibodies.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Monoclonal antibodies.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Monoclonal antibodies.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Monoclonal antibodies.
Shares FOLFOX (5-FU, leucovorin, oxaliplatin), Monoclonal antibodies.